Lymphocyte-to-procalcitonin ratio: a new predictor of prognosis in COVID-19.

ABSTRACT:

Background

COVID-19 pneumonia remains a major global health concern and is characterized by a dysregulated inflammatory response. This study aimed to evaluate and compare the lymphocyte-to-procalcitonin ratio (LPCT) with conventional inflammatory markers in predicting clinical outcomes in patients with COVID-19.

Methods

This retrospective observational study was conducted at a tertiary university hospital in Turkey. Adult patients diagnosed with COVID-19 were included between June 1, 2020, and June 1, 2022. Patient demographic and clinical data, including laboratory parameters and comorbidities, were collected from electronic medical records. The primary outcome was in-hospital mortality, while the secondary outcome was the prediction of the requirement for invasive mechanic

SUBMITTER: Oguzlar FC 

PROVIDER: S-EPMC12512254 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature